Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Tatiana I. Lobanova"'
Autor:
Ekaterina I. Usikova, Irina V. Galtseva, Andrey N. Sokolov, Nikolai M. Kapranov, Irina A. Lukyanova, Tatiana I. Lobanova, Julia O. Davidova, Ksenia Zarubina, Vera V. Troitskaya, Olga A. Gavrilina, Elena N. Parovichnikova, Larisa A. Kuzmina, Valeriy G. Savchenko, Sergei M. Kulikov, Sergey N. Bondarenko
Publikováno v:
Cellular Therapy and Transplantation. 9:38-46
Autor:
Andrey N. Sokolov, Tatiana I. Lobanova, Gennadiy M. Galstyan, Sergei M. Kulikov, Sergey K. Kravchenko, Zalina T. Fidarova, Julia Chabaeva, Vera V. Troitskaya, Olga A. Gavrilina, Elena O. Gribanova, Elena N. Parovichnikova, Valeriy G. Savchenko, A V Kokhno
Publikováno v:
Blood. 134:5136-5136
Background Acute myeloid leukemia (AML) in older adults is a biologically and clinically distinct entity. These patients often have comorbidities, and their treatment must be chosen with caution. In AML patients over 60y old, cure rates are under 10%
Autor:
Mikhail Yu. Drokov, Ulyana V. Maslikova, N N Popova, Z V Konova, Tatiana I. Lobanova, Irina V. Galtseva, Ekaterina Mikhaltsova, V A Vasilyeva, Olga Koroleva, Elena N. Parovichnikova, Larisa A. Kuzmina, Julia O. Davydova, Olga S. Starikova, Maria V. Nareyko, Valeriy G. Savchenko, Ekaterina I. Usikova, Nikolay M. Kapranov, Anna Dmitrova
Publikováno v:
Blood. 134:4562-4562
Introduction. Allogeneic hematopoietic stem cell transplantation (allo-HSCT) could be curative for acute myeloid leukemia (AML) patients. However, the disease relapse after allo-HSCT lead to poor outcomes almost in all cases. Minimal residual disease
Autor:
Sergei M. Kulikov, Andrey N. Sokolov, Valery G. Savchenko, Tatiana I. Lobanova, Julia O. Davydova, Elena N. Parovichnikova, Irina V. Galtseva, Vera V. Troitskaya, Nikolay M. Kapranov
Publikováno v:
Blood. 134:5183-5183
Introduction. Presence of measurable by flow cytometry (FC) residual disease (MRD) is a well-known risk factor in AML patients (pts), which is associated with adverse prognosis. The main idea in MRD by FC is searching for leukemia-associated immunoph
Autor:
Lubov Grebenyuk, Murat Vagida, Elena A. Mikhaylova, Tatiana N. Obukhova, Yuliya O. Davydova, Tatiana I. Lobanova, Anton V. Luchkin, Anastasia V. Abramova, Alina E. Krasilnikova, Valery G. Savchenko, Elena N. Parovichnikova, Irina V. Galtseva, Vera V. Troitskaya, Zalina T. Fidarova, Nikolay M. Kapranov
Publikováno v:
Blood. 132:5108-5108
Background. New insight into pathogenesis of aplastic anemia (AA) in conjunction with effectiveness of Eltrombopag allowes to recommend it for initial treatment of de novo AA. However, eltrombopag was an attractive option for patients at different st
Autor:
Tatiana I. Lobanova, Elena N. Parovichnikova, Larisa A. Kuzmina, Irina V. Galtseva, Valery G. Savchenko, Sergei M. Kulikov, Irina A. Lukyanova, Yuliya O. Davydova, Nikolay M. Kapranov, Vera V. Troitskaya
Publikováno v:
Blood. 132:2808-2808
Introduction. Minimal residual disease (MRD) detection by multicolor flow cytometry (MFC) after early induction or consolidation AML therapy is a well known factor of adverse prognosis, especially in intermediate risk group. New assessment of respons
Autor:
Irina A. Lukyanova, Andrey N. Sokolov, Valery G. Savchenko, Roman V. Tivikov, Tatiana N. Obukhova, Nikolay M. Kapranov, Tatiana I. Lobanova, Vera V. Troitskaya, Irina V. Galtseva, A V Kokhno, Elena N. Parovichnikova, Yuliya O. Davydova
Publikováno v:
Blood. 132:1495-1495
Background. The recent ELN recommendations (2017) have introduced new criteria of response in AML - complete remission with MRD-negativity (CR/MRD-neg). It's a well-known fact that AML with different cytogenetics has different chemosensitivity, and s
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.